← ANALYST RATINGS · TIPRANKS
Ocugen (OCGN): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $10.33, the highest $11.00, the lowest $10.00. The average is +1,224.8% from the last price of $0.78.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.89 → $0.86−2.6% | Hold | +10.5% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.87 → $0.82−6.4% | Hold | +4.6% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.88 → $0.83−4.9% | Hold | +6.8% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.87 → $0.82−5.4% | Hold | +5.1% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.92 → $0.86−5.9% | Hold | +10.5% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.88 → $0.82−6.8% | Hold | +4.6% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $10.00 | Buy | +1,182.1% | Reiterated | 01.10.26on TipRanks 10:10 | −3.1%next day +1.3% · 5 days −3.6% | ↗ |
| Whitney Ijem★★★★★★★★★★#537 · hits 48% · avg +20.2% | Canaccord Genuity | $11.00 | Buy | +1,310.3% | Reiterated | 29.09.26on TipRanks Sep 30 09:15 | +6.0%next day −5.3% · 5 days −6.5% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $10.00 | Buy | +1,182.1% | Reiterated | 29.09.26on TipRanks Sep 30 03:50 | +6.0%next day −5.3% · 5 days −6.5% | ↗ |
| Robert LeBoyer★★★★★★★★★★#12335 · hits 27% · avg −14.2% | Noble Financial | $12.00 | Buy | +1,438.5% | Reiterated | 28.09.26on TipRanks 09:10 | +1.7%next day +6.0% · 5 days −0.2% | ↗ |
| Michael Okunewitch★★★★★★★★★★#11525 · hits 36% · avg −3.3% | Maxim Group | $8.00 | Buy | +925.6% | Reiterated | 16.09.26on TipRanks 13:45 | +0.9%next day +2.1% · 5 days −1.9% | ↗ |
| Daniil Gataulin★★★★★★★★★★#2392 · hits 39% · avg +14.9% | Chardan Capital | $7.00 | Buy | +797.4% | Reiterated | 07.05.26on TipRanks 08:30 | −0.7%next day +4.0% · 5 days −0.9% | ↗ |
| Elemer Piros★★★★★★★★★★#12258 · hits 35% · avg −8.3% | Lucid Capital | $15.00 → $22.00+46.7% | Buy | +2,720.5% | Reiterated | 11.03.26on TipRanks Mar 12 01:13 | +30.1%next day +3.3% · 5 days +1.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Ocugen
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $10.20 at a price of $1.03 (+890.3%); now: $10.20 at $0.78 (+1,207.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 4 | 3 | 2 | 7 | 8 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.06 (from $-0.08 to $-0.04). Last quarter: $-0.07.
Sales
Next quarter’s sales estimate — $1M (from $1M to $2M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About Ocugen
- CEO: Shankar Musunuri
- Employees: 116
- 263 Great Valley Parkway, Malvern, PA, 19355, US
- www.ocugen.com
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
Data from the stock’s TipRanks forecast page, read 118 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗